NCT01035749View on ClinicalTrials.gov

Study of GSK Biologicals' Pandemic Influenza (H1N1) Candidate Vaccine in Children Aged 10 to Less Than 18 Years

PHASE2CompletedINTERVENTIONAL
Enrollment

310

Participants

Timeline

Start Date

February 1, 2010

Primary Completion Date

September 27, 2010

Study Completion Date

May 10, 2011

Conditions
Influenza
Interventions
BIOLOGICAL

GSK Biologicals' Influenza investigational vaccine GSK2340274A

One or two doses administered intramuscularly

BIOLOGICAL

GSK Biologicals' Influenza investigational vaccine GSK2340273A

Two doses intramuscularly

BIOLOGICAL

Placebo (saline)

One dose intramuscularly

Trial Locations (9)

50106

GSK Investigational Site, Tartu

919 43

GSK Investigational Site, Cífer

026 01

GSK Investigational Site, Dolný Kubín

929 01

GSK Investigational Site, Dunajská Streda

018 51

GSK Investigational Site, Nová Dubnica

915 01

GSK Investigational Site, Nové Mesto nad Váhom

020 01

GSK Investigational Site, Púchov

034 01

GSK Investigational Site, Ružomberok

911 01

GSK Investigational Site, Trenčín

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY